PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib

Sorafenib is currently the only systemic agent approved for treatment of advanced hepatocellular carcinoma (HCC). However, intrinsic and acquired resistance to sorafenib remains a great challenge with respect to improving the prognoses of patients with HCC. The cyto-protective functions of autophagy...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cell Death Dis
Egile Nagusiak: Zhang, Kai, Chen, Jing, Zhou, Hao, Chen, Ying, Zhi, Yingru, Zhang, Bei, Chen, Longbang, Chu, Xiaoyuan, Wang, Rui, Zhang, Chunni
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833744/
https://ncbi.nlm.nih.gov/pubmed/29472524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-018-0344-0
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak